Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.48 |
| ▸ | USP2 | O75604 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25255709 | 0.86 | USP2 (0.47) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL29497111 | 0.86 | RORC (0.46) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL25295819 | 0.86 | RORC (0.46) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL25301345 | 0.85 | DRD2 (0.51) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL31307991 | 0.83 | CYP2D6 (0.46) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL30409672 | 0.82 | USP2 (0.40) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL25146298 | 0.82 | USP2 (0.40) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL30395730 | 0.82 | ALDH1A1 (0.42) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL25145879 | 0.82 | ALDH1A1 (0.42) | CYP2D6USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL25146295 | 0.81 | MGLL (0.40) | CYP2D6USP2CYP3A4TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CYP2D6 65/4885USP2 3410/4885CYP3A4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.